Top stories in cardiology: Device for transesophageal echocardiogram receives FDA clearance, search continues for ideal diet to reduce CVD risk

Among the top stories in cardiology is the FDA granting 510(k) clearance for a single-use disposable camera system used during a transesophageal echocardiogram . While healthy dietary patterns are critical for patients’ future health, the perfect pattern has yet to be determined. Other top stories include treating patients who have depression and recent acute coronary syndrome with escitalopram resulted in a lower risk for major adverse cardiac events, women with STEMI were less likely than men to be treated with appropriate invasive procedures or medication and were more likely to have poor outcomes after 6 months, and Etripamil, a novel fast-acting calcium channel blocker, quickly terminated supraventricular tachycardia.

Device for transesophageal echocardiogram receives FDA clearance

Visura Technologies announced that a single-use disposable camera system used during a transesophageal echocardiogram has received 510(k) clearance from the FDA. Read More.

Search continues for ideal diet to reduce CVD risk

Healthy dietary patterns are critical for the future health of patients, but the perfect dietary pattern still has yet to be determined, according to a review published in the Journal of the American College of Cardiology. Read More.

Escitalopram reduces risk for cardiac events in patients with depression, ACS

Patients with depression and recent acute coronary syndrome who were treated with escitalopram had lower risk for major adverse cardiac events compared with those given placebo, according to a study published in JAMA. Read More.

In patients with STEMI, women undertreated, face worse outcomes

Among patients with STEMI, women were less likely than men to be treated with appropriate invasive procedures or medication and were more likely to have poor outcomes 6 months after the event, researchers reported. Read More.

NODE-1: Etripamil may halt supraventricular tachycardia

Etripamil, a novel fast-acting calcium channel blocker administered via nasal spray, quickly terminated supraventricular tachycardia, according to the results of the NODE-1 trial. Read More.